Literature DB >> 2160881

Diarrhea as a presenting symptom of hepatocellular carcinoma.

J Bruix1, A Castells, X Calvet, F Feu, C Bru, M Solé, M Bruguera, J Rodés.   

Abstract

The clinical manifestations of hepatocellular carcinoma (HCC) are highly nonspecific since they usually mimic those of hepatic cirrhosis, which frequently underlies this neoplasm. The fact that some HCC patients present with severe diarrhea, an unusual symptom in liver cirrhosis, prompted us to determine the prevalence of diarrhea in a series of 23 consecutive HCC patients and compare it with that of a control group formed by cirrhotic patients without HCC, matched by age, sex, and etiology of the liver disease. All the patients were interviewed about the existence of diarrhea (defined as the presence of three or more loose stools per day appearing over three or more days) in the three months prior to admission. Both groups of patients were similar in regards to the degree of liver failure and presence of diarrhea-favoring factors. By contrast, diarrhea was significantly more frequent among HCC cases than among cirrhotics without HCC (47.8% vs 8.7%, P less than 0.005). HCC patients with diarrhea exhibited higher alkaline phosphatase and bilirubin levels and worse liver function, assessed by the Child-Pugh's classification, than patients without diarrhea. However, neither tumor size, vascular invasion, or the degree of tumor differentiation were significantly different between these two groups of HCC patients. These results show that diarrhea is a frequent manifestation of HCC in patients with cirrhosis. Therefore, the development of HCC in these patients should be suspected upon the appearance of diarrhea.

Entities:  

Mesh:

Year:  1990        PMID: 2160881     DOI: 10.1007/BF01540166

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  9 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Early recognition of hepatocellular carcinoma.

Authors:  K Okuda
Journal:  Hepatology       Date:  1986 Jul-Aug       Impact factor: 17.425

Review 3.  Cirrhosis and the aetiology of hepatocellular carcinoma.

Authors:  P J Johnson; R Williams
Journal:  J Hepatol       Date:  1987-02       Impact factor: 25.083

4.  Hepatocellular carcinoma and the watery diarrhea syndrome.

Authors:  A Solinas; L Biscarini; A Morrelli; A Del Favero
Journal:  Arch Surg       Date:  1988-01

5.  Transection of the oesophagus for bleeding oesophageal varices.

Authors:  R N Pugh; I M Murray-Lyon; J L Dawson; M C Pietroni; R Williams
Journal:  Br J Surg       Date:  1973-08       Impact factor: 6.939

6.  Hepatocellular carcinoma presenting with intractable diarrhea. A radiologic-pathologic correlation.

Authors:  E Steiner; P Velt; O Gutierrez; S Schwartz; W Chey
Journal:  Arch Surg       Date:  1986-07

7.  Long survival of diarrhea-associated hepatocarcinoma treated with Adriamycin and indomethacin. A case report.

Authors:  J Saban; D Boixeda; A Moreno; R Barcena; M Serrano-Rios
Journal:  Am J Clin Pathol       Date:  1986-08       Impact factor: 2.493

8.  Technetium-99m DISIDA hepatobiliary agent in diagnosis of hepatocellular carcinoma: relationship between detectability and tumor differentiation.

Authors:  X Calvet; F Pons; J Bruix; C Bru; F Lomeña; R Herranz; M Brugera; R Faus; J Rodes
Journal:  J Nucl Med       Date:  1988-12       Impact factor: 10.057

9.  Clinical features of hepatocellular carcinoma: review of 211 patients in Hong Kong.

Authors:  C L Lai; K C Lam; K P Wong; P C Wu; D Todd
Journal:  Cancer       Date:  1981-06-01       Impact factor: 6.860

  9 in total
  3 in total

Review 1.  Guide for diagnosis and treatment of hepatocellular carcinoma.

Authors:  Magdy Hamed Attwa; Shahira Aly El-Etreby
Journal:  World J Hepatol       Date:  2015-06-28

2.  Diagnosis of hepatocellular carcinoma.

Authors:  Eldad S Bialecki; Adrian M Di Bisceglie
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

Review 3.  Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.

Authors:  Bruno Sangro; Stephen L Chan; Tim Meyer; María Reig; Anthony El-Khoueiry; Peter R Galle
Journal:  J Hepatol       Date:  2020-02       Impact factor: 25.083

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.